Building a Sustainable Growth Company
|
|
- MargaretMargaret Lucas
- 5 years ago
- Views:
Transcription
1 Building a Sustainable Growth Company 1
2 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company s strategies, positioning, resources, capabilities and expectations for future performance; and the Company's outlook and financial and other guidance. These statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from expectations. Risks and uncertainties that could adversely affect the Company s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include, without limitation: the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees; U.S., European and worldwide economic conditions and related uncertainties; the Company s reliance on third party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; uncertainties regarding healthcare reform legislation, including associated tax provisions, or budget reduction or other cost containment efforts; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated; the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally, including the effect of exchange rate fluctuations on those operations; manufacturing risks, including the Company s reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company s products; the Company s leverage risks, including the Company s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; competition; and the Company s ability to attract and retain qualified personnel. The risks included above are not exhaustive. Other factors that could adversely affect the company's business and prospects are described in filings made with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. Hologic, Aptima, Aptima Combo 2, Genius, Horizon, MyoSure, NovaSure, Panther, Selenia, The Science of Sure, ThinPrep, Tigris and associated logos, as may be used in this presentation, are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Procleix is a trademark of Grifols Diagnostic Solutions Inc. 2
3 Non-GAAP Financial Measures Hologic has presented the following non-gaap financial measures in this presentation: constant currency revenues; non-gaap gross margin; non-gaap operating expenses; non-gaap operating margin; non-gaap net income; non-gaap EPS; adjusted EBITDA; and return on invested capital (ROIC). The Company defines its non-gaap net income, EPS, and other non-gaap financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill and intangible assets; (ii) additional depreciation expense from acquired fixed assets and accelerated depreciation related to consolidation and closure of facilities; (iii) non-cash interest expense related to amortization of the debt discount from the equity conversion option of the convertible notes; (iv) restructuring and divestiture charges and facility and consolidation charges; (v) debt extinguishment losses and related transaction costs; (vi) unrealized gains/losses attributable to recording forward foreign currency contracts to fair value for which the company has not elected hedge accounting; (vii) litigation settlement charges (benefits); (viii) other-than-temporary impairment losses on investments and realized gains resulting from the sale of investments; (ix) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company s core business results; and (x) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-gaap net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-gaap net income. The Company defines ROIC as its net operating profit after tax on a trailing twelve month basis divided by average net debt plus average stockholders equity. These non-gaap financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The company s definition of these non-gaap measures may differ from similarly titled measures used by others. The non-gaap financial measures used in this presentation adjust for specified items that can be highly variable or difficult to predict. The company generally uses these non-gaap financial measures to facilitate management s financial and operational decision-making, including evaluation of Hologic s historical operating results, comparison to competitors operating results and determination of management incentive compensation. These non-gaap financial measures reflect an additional way of viewing aspects of the company s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic s business. Because non-gaap financial measures exclude the effect of items that will increase or decrease the company s reported results of operations, management strongly encourages investors to review the company s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non- GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this presentation. 3
4 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 4
5 Hologic Today Innovative healthcare company with market-leading products for early detection and intervention, with a strong position in women s health Divisional Revenue FY15 Types of Revenue FY15 Breast Health 39% Skeletal 4% Surgical 12% Diagnostics 45% Service 16% Capital 23% Consumables 61% New management team leading transition from turnaround to sustainable growth Revenue of $2,825 million (+5.1% CC) and EPS of $1.935 (+17.2% CC) expected in FY16* Tremendous earnings power and cash flow generation 33.7% non-gaap operating margin, $498 million free cash flow through 9 months FY16 * Based on midpoints of guidance provided by press release on 7/27/16. Presentation here is not, and should not be construed as, reaffirmation of guidance. Hologic fiscal year ends in September. 5
6 Encouraging Progress in Turnaround U.S. businesses improving more rapidly than expected, with encouraging profit benefit and growth potential Stabilizing mature franchises ThinPrep liquid cytology NovaSure for abnormal uterine bleeding Maximizing growth drivers Genius 3D Mammography in breast health Panther system in molecular diagnostics MyoSure in GYN surgical Strengthening the balance sheet 6
7 From Turnaround to Sustainable Growth Demonstrating consistent quarterly sales growth $700 $694 10% $703 10% $695 7% $693 6% $717 3% $650 $631 $613 $626 $622 $612 (3%) $625 2% $633 1% $640 3% $653 7% $655 5% $600 $550 (3%*) 2%* 1%* 3%* 8%* 7%* 12%* 12%* 8%* 6%* 4%* $ Q1 Q2 Q3 Q4 * Constant currency growth. Numbers above bars are total GAAP revenue growth as reported with the exception of 4Q FY14, which excludes ~$20 million one-time contribution from restructuring of Roka license. Percentage changes versus prior year periods. 7
8 Broad, Deep Quarterly Sales Growth Dx Breast Surgical Skeletal Total US Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q Dx Breast Surgical Skeletal Total OUS Dx Breast Surgical Skeletal Worldwide 0-4.9% 5-9.9% 10%+ decline * Constant currency revenue change with the exception of 4Q FY14, which excludes ~ $20 million one-time contribution from restructuring of Roka license. 8
9 Future Opportunities for Revenue and EPS Growth Continued growth from U.S. commercial execution, plus: R&D pipeline International expansion Operational efficiencies Tax Capital deployment 9
10 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 10
11 Sales Stabilizing Leading product for liquid Pap testing U.S. market share >75%* Headwinds from longer testing intervals Re-energized we love ThinPrep focus Domestic market share gains International penetration in early stages Cytology and Perinatal sales +3.5% through 9 months FY16** Future priorities Increase co-testing penetration Invest in marketing, R&D to strengthen brand Grow internationally $600 $500 $400 $300 Cytology & Perinatal Sales $556 $519 $485 $472 (7%**) (7%**) 1%** * Hologic estimate for the US market on a unit basis in ** Constant currency growth. 11
12 Sales Stabilizing Leading solution for abnormal uterine bleeding U.S. market share >65%* Better commercial execution Revitalized sales force» Improved incentive plans, lowered attrition» Expanded clinical specialists in field NovaSure sales +10.4% through 9 months FY16** Future priorities Continue gaining market share Expand U.S. market versus alternative solutions Penetrate developed markets OUS $300 $250 $200 $150 $100 $259 NovaSure Sales $235 $219 $217 (9%**) (7%**) 2%** * Hologic estimate for the US market on a unit basis in ** Constant currency growth. 12
13 Growth Driver: Innovative technology addresses limitations of conventional mammography Landmark JAMA study Genius TM mammograms detected 41% more invasive breast cancers, while reducing recall rates by 15% Global breast imaging growing strongly Publication of clinical benefits High-impact marketing campaign CMS reimbursement Inferior competitive entrants Breast imaging sales +8.0% through 9 months FY16* $900 $800 $700 $600 $500 $682 Breast Imaging Sales $756 $716 5%* 5%* $884 19%* * Constant currency growth. 13
14 Significant Opportunity for Continued Genius TM Growth U.S. market leader with ~60% share* Gained ~3 share points in FY15 Product advantages include superiority claim, faster scan time Customers ranked Hologic highest in all 11 measures in KLAS study** Significant U.S. market penetration still ahead as market upgrades to 3D Full conversion implies >$3.5 billion opportunity Plus growing service annuity Nascent international opportunity U.S. Penetration Metrics as of September 2015 HOLX 3D Installed Base HOLX 2D Installed Base Total Mammo Units HOLX 3D of HOLX Installed Base HOLX 3D of Total Market 2,400 6,200 14,500 ~28% ~17% * Hologic estimate for the US market on a unit basis in **Women s Imaging. Are the New Technologies Delivering Promised Benefits? August Performance Report KLAS Enterprises, LLC. All rights reserved. 14
15 System Driving Molecular Growth Best-in-class automation and workflow More than 1,000 units in field globally #1 in CT/NG, HPV and Trich testing in U.S. Growing assay menu and utilization Average Panther system generated >$170,000 of revenue in FY15 Molecular sales +7.2% through 9 months FY16* Future priorities Maximize Panther placements Drive adoption of current and future portfolio, including viral load assays Launch next-generation Panther Fusion Build international business $500 $450 $400 $350 $447 Molecular Sales $487 $459 2%* 7%* 2013** 2014*** 2015 * Constant currency growth. ** Excluding divested Lifecodes business in FY13. *** Excluding ~$20 million one-time contribution from restructuring of Roka license in 4QFY14. 15
16 Driving Growth in GYN Surgical Leading hysteroscopic tissue removal solution for fibroids and polyps Strong recent growth Accelerated customer adoption and improved utilization both domestically and overseas MyoSure sales +34.7% through 9 months FY16** Future priorities Continue broadening usage Maximize benefits of clinical specialists Expand internationally $140 $120 $100 $80 $60 $40 $20 $0 $39 MyoSure Sales $116 $87 $68 77%* 27%* 35%* * Constant currency growth. 16
17 Strengthening the Balance Sheet Strong cash flows enabled significant improvements in FY15 Re-financed bank loan and high-yield bond» Lowered interest expense, increased financial flexibility Reduced total debt by $628 million» Pre-paid $300 million of former term loan in Q1» Repurchased $300 million of 2010 convertible notes in Q4 Continued strengthening in FY16 Total debt reduced by $218 million Q3 YTD» Repurchased $90 million of 2010 convertible notes, $137 million of 2012 convertible notes in Q2 Q3 FY16 net debt $3 billion, leverage ratio 3.0x» Targeting 2.5x by end of FY17 ROIC of 12.3% in Q3 FY16 improved 170 bps $5.0 $4.0 $3.0 $2.0 $1.0 $0.0 $ x Net Debt and Leverage Ratio* $ x $ x $3.1 $ x 3.0x YTD 3Q16 * Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA. 17
18 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 18
19 Revitalizing Research and Development Committed to organic growth via shortand long-term R&D Upgrading talent and processes Focused on optimizing investment Key programs build on strong existing product and channel platforms Diagnostics» 3 viral load assays, test for Mycoplasma genitalium detection all launched in Europe» Complementary women s health tests» Panther Fusion to provide new chemistry and assay format Breast health» Affirm prone biopsy system with 3D compatibility launched» Brevera next-generation biopsy device MyoSure Reach in GYN surgical 19
20 International Opportunity Largely Untapped Only 24% of revenues generated OUS in FY15 Early signs of progress, but will take time Key priorities Mammography Cytology» More than 24,000 units in 10 focus» More than 30 million liquid Pap tests in 10 markets, only 1/3 are 2D/3D focus markets, Hologic share only ~40%» Hologic share less than half of U.S. level» Plus more than 140 million conventional» Optimize distributor network and Pap tests relationships» And long-term opportunity to increase Molecular diagnostics adherence to screening» Panther well-suited to smaller, hospitalbased Surgical customers» More than 85% of business comes from» All three viral load assays recently CEmarked U.S. today» Continue executing on menu expansion 20
21 Multiple Opportunities to Increase Profitability Building on industry-leading margins Operational Improvements Realize efficiencies from higher U.S. sales volumes Achieve productivity goals across plant network Improve inventory management Implement central procurement Out-source Skeletal manufacturing Consolidate headquarters Leverage G&A expenses Tax Re-financing of bank debt loosened covenants In near-term, re-align legal entities and optimize product and transaction efficiencies Reduced effective rate by >200 bps in last year Over long-term, migrate infrastructure and decisionmaking as OUS revenue grows Capital Deployment Priority remains to reduce debt, with focus on dilutive convertible notes Capabilities for tuck-in business development rebuilt in divisions Repurchased $250 million of stock in FY16 New $500 million program authorized by Board 21
22 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 22
23 Revenue Highlights 3Q Fiscal 2016 Revenue ($M) 3Q16 Reported vs. 3Q15 Non-GAAP CC vs. 3Q15 YTD 3Q16 Reported vs. YTD 3Q15 CC vs. YTD 3Q15 Diagnostics $ % 1.2% $ % 2.7% Breast Health $ % 1.1% $ % 6.2% GYN Surgical $ % 19.8% $ % 18.2% Skeletal Health $ % 4.8% $ % 1.1% Total Revenue $ % 3.6% $2, % 5.9% US $ % 4.7% $1, % 9.2% OUS $152.5 (1.2%) (0.4%) $448.0 (7.5%) (4.3%) 23
24 Financial Overview 3Q Fiscal 2016 In millions, except EPS 3Q16 Non-GAAP vs. 3Q15 YTD 3Q16 YTD vs. 3Q15 Revenues $ % $2, % Gross Margin 65.7% 50 bps 65.6% 160 bps Operating Expenses $ % $ % Operating Margin 33.8% 60 bps 33.7% 50 bps Net Income $ % $ % Diluted EPS $ % $ % EBITDA $ % $ % 24
25 2016 Financial Guidance Full Year (Non-GAAP*) 4Q (Non-GAAP*) In millions, except EPS 2016 Guidance Reported vs CC vs Q16 Guidance Reported vs CC vs Revenues $2,820 $2, % % $714 $ % % Diluted EPS $1.93 $ % % $0.49 $ % % *Guidance provided by press release on 7/27/16. Presentation here is not, and should not be construed as, re-affirmation of guidance. Guidance assumes diluted shares outstanding of ~288 million for the full year and an annual effective tax rate of approximately 32%. 25
26 Early Perspective on FY17 For Hologic overall, reasonable to assume slower revenue growth in 2017 than in 2016 Key top-line variables include: Growth Drivers Breast Health product and service revenue Continued progress in multiple international segments Key molecular diagnostic products Headwinds Blood screening Discontinued CF product Surgical market share gains New products: Affirm prone biopsy system, Brevera, viral load tests, MyoSure Reach 26
27 Strong Growth in Annual Revenues and Profits $2,800 Revenue* $2,705 34% Operating Margin* 33.3% $1.70 EPS* $1.67 $2,600 $2,492 $2,511 32% 32.3% 32.0% $1.50 $1.50 $1.46 $2,400 30% $1.30 $2,200 $2,000 28% $ * Total GAAP revenue growth as reported with the exception of FY14, which excludes ~$20 million one-time revenue contribution from restructuring of Roka license that also increased operating margin and added $0.05 to EPS in FY14. Operating margin and EPS are non-gaap. 27
28 Other Financial Highlights 77% of Hologic revenue was recurring (and growing) through 9 months FY16 EPS expected to increase much faster than revenue Gross, operating leverage Tax, interest expense and share count Strong Cash Flows, Minimal CapEx (7%**) (7%**) 1%** 786 Business generates tremendous free cash flow Opportunities to strengthen the balance sheet, deploy capital smartly Non-GAAP Net Income Free CF Operating CF
29 Industry-Leading Margins Improving Further Gains from product and geographic mix, productivity initiatives 70% 60% 62.2% 63.4% 64.2% 65.6% 50% 40% 30% 20% 10% 32.3% 32.0% 33.3% 33.7% 16.2% 16.2% 17.9% 19.8% YTD Non-GAAP GM% Non-GAAP OI% Non-GAAP NI% 29
30 Strengthening Balance Sheet, ROIC $5.0 $4.0 $3.0 $2.0 Net Debt and Leverage Ratio* $4.0 $ x $3.1 $ x 3.3x 3.0x 13.0% 12.0% 11.0% 10.0% 9.0% 8.3% ROIC** 9.3% 10.9% 12.3% $ % 7.0% $ YTD 3Q16 6.0% YTD 3Q16 * Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA. ** ROIC on a Trailing Twelve Month basis, defined as adjusted net operating profit after tax divided by average net debt plus stockholders equity. 30
31 A Bright Future Ahead We have accomplished a lot in a short amount of time Stabilizing mature businesses in the U.S. Maximizing domestic growth drivers Strengthening the balance sheet But we still have significant runway ahead of us R&D pipeline International expansion Operational efficiencies Tax Capital deployment As we transition from a turnaround story to a sustainable growth company With tremendous earnings power and cash generation capabilities 31
32 For more information: Michael Watts VP, Investor Relations and Corporate Communications
33 Financial Appendix 33
34 Overview of Hologic s Debt Senior term loan $1.425 billion in annual payments over the next four years:» $75, $112.5, $150, and $1,087.5 million» LIBOR % Revolving credit facility ($1.0 billion undrawn) 2% convertible notes Now $793 million, down from $1.32 billion $60 million (2010 notes) due 2037» Strike price of $23.03 callable in December 2016 $370 million (2013 notes) due 2043» Strike price of $38.59 callable in December 2017» 0% cash coupon; accretion 4% $363 million (2012 notes) due 2042» Strike price of $31.18 callable in March 2018 $1 billion senior notes due % interest $200 million accounts receivable securitization program 34
35 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q13 12/29/12 2Q13 3/30/13 3Q13 6/29/13 4Q13 9/28/13 Full Year % of Revenue Share Business Segment Revenues Cytology & Perinatal $137.0 $124.9 $132.2 $124.8 $ % Molecular Diagnostics % Blood Screening % Total Diagnostics $305.9 $296.5 $297.4 $290.0 $1, % Breast Imaging $173.8 $171.3 $182.9 $188.0 $ % Interventional Breast Solutions % Other % Total Breast Health $220.8 $220.1 $230.0 $234.2 $ % Surgical $80.9 $73.7 $75.8 $76.7 $ % Skeletal Health $23.7 $22.4 $22.9 $21.2 $ % Total Revenues $631.4 $612.7 $626.1 $622.1 $2,
36 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q14 12/28/13 2Q14 3/29/14 3Q14 6/28/14 4Q14 9/27/14 Full Year % of Revenue Share Business Segment Revenues Cytology & Perinatal $121.6 $119.4 $122.7 $121.0 $ % Molecular Diagnostics * 478.8* 18.9% Blood Screening % Total Diagnostics $285.7 $290.8 $293.1 $317.2* $1,186.8* 46.9% Breast Imaging $178.0 $189.4 $192.7 $196.3 $ % Interventional Breast Solutions % Other % Total Breast Health $226.5 $238.7 $238.0 $241.5 $ % Surgical $78.9 $72.0 $78.5 $78.5 $ % Skeletal Health $21.4 $23.5 $23.0 $23.4 $ % Total Revenues $612.4 $625.0 $632.6 $660.6* $2,530.7* * Excluding the $20.1 million revenue benefit related to an amendment to the Company s license agreement with Roka Bioscience (all of which was in the U.S.), 4Q14 molecular diagnostics revenue would have been $117.2 million, total diagnostics revenue would have been $297.1 million, and total revenues would have been $640.5 million. Similarly, FY14 molecular diagnostics revenue would have been $458.7 million, total diagnostics revenue would have been $1,166.7 million, and total revenues would have been $ million. 36
37 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q15 12/27/14 2Q15 3/28/15 3Q15 6/27/15 4Q15 9/26/15 Full Year % of Revenue Share Business Segment Revenues Cytology & Perinatal $120.1 $113.3 $118.1 $120.8 $ % Molecular Diagnostics % Blood Screening % Total Diagnostics $304.1 $296.7 $306.9 $ , % Breast Imaging $197.5 $211.0 $ % Interventional Breast Solutions % Other % Total Breast Health $242.0 $255.5 $279.6 $286.3 $1, % GYN Surgical $84.4 $79.1 $ % Skeletal Health $22.3 $24.2 $ % Total Revenues $652.8 $655.5 $693.9 $702.8 $2,
38 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q16 12/26/15 2Q16 3/26/16 3Q16 6/25/16 4Q16 9/24/16 Year to Date % of Revenue Share Business Segment Revenues Cytology & Perinatal $120.4 $116.1 $122.2 $ % Molecular Diagnostics % Blood Screening % Total Diagnostics $310.7 $304.4 $309.9 $ % Breast Imaging $218.1 $232.3 $ % Interventional Breast Solutions % Other % Total Breast Health $262.2 $275.8 $282.5 $ % GYN Surgical $98.8 $90.9 $102.0 $ % Skeletal Health $23.5 $22.2 $23.0 $ % Total Revenues $695.2 $693.3 $717.4 $2,
39 Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended June 25, 2016 June 27, 2015 GROSS PROFIT GAAP gross profit $393.1 $378.7 Adjustments: Amortization of intangible assets $77.9 $73.1 Incremental depreciation expense Integration/consolidation costs Non-GAAP gross profit $471.5 $452.7 GROSS MARGIN PERCENTAGE GAAP gross margin percentage 54.8% 54.6% Impact of adjustments above 10.9% 10.6% Non-GAAP gross margin percentage 65.7% 65.2% OPERATING EXPENSES GAAP operating expenses $253.7 $262.7 Adjustments: Amortization of intangible assets (21.9) (27.4) Incremental depreciation expense (0.9) (1.0) Integration/consolidation costs (0.2) - Restructuring and divestiture charges (1.5) (11.9) Other - - Non-GAAP operating expenses $229.2 $222.4 OPERATING MARGIN GAAP income from operations $139.4 $116.0 Adjustments to gross profit as detailed above Adjustments to operating expenses as detailed above Non-GAAP income from operations $242.3 $230.3 Continued on next page 39
40 Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended June 25, 2016 June 27, 2015 OPERATING MARGIN PERCENTAGE GAAP operating margin percentage 19.4% 16.7% Impact of adjustments above 14.4% 16.5% Non-GAAP operating margin percentage 33.8% 33.2% INTEREST EXPENSE GAAP interest expense $39.1 $52.4 Adjustments: Non-cash interest expense relating to convertible notes (5.2) (9.2) Debt transaction costs (4.6) Non-GAAP interest expense $33.9 $38.6 PRE-TAX INCOME GAAP pre-tax earnings (loss) $101.1 $46.7 Adjustments to pre-tax earnings as detailed above Debt extinguishment loss Gain on sale of available-for-sale marketable security - - Unrealized gains on forward foreign currency contracts (0.2) - Non-GAAP pre-tax income $209.0 $193.0 NET INCOME GAAP net income $84.8 $29.4 Adjustments to GAAP net income (loss) as detailed above Income tax effect of reconciling items 2 (47.6) (48.8) Non-GAAP net income $145.1 $126.9 EARNINGS PER SHARE GAAP earnings per share Diluted $0.30 $0.10 Adjustments to net earnings (loss) (as detailed below) Non-GAAP earnings per share Diluted 1 $0.51 $0.43 ADJUSTED EBITDA Non-GAAP net income $145.1 $126.9 Interest expense, net, not adjusted above Provision for income taxes Depreciation expense, not adjusted above Adjusted EBITDA $262.5 $ Non-GAAP earnings per share was calculated based on 287,857 and 287,580 weighted average diluted shares outstanding for the three months ended March 26, 2016 and March 28, To reflect an annual effective tax rate of 32.75% on a non-gaap basis for fiscal 2016 and 34.25% on a non-gaap basis for fiscal
Building a Sustainable Growth Company
Building a Sustainable Growth Company William Blair 36 th Annual Growth Stock Conference 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties,
More informationBuilding a Sustainable Growth Company
Building a Sustainable Growth Company 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans,
More informationBuilding a Track Record of Sustainable Growth
Building a Track Record of Sustainable Growth William Blair Growth Stock Conference June 14, 2018 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and
More informationBuilding a Track Record of Sustainable Growth
Building a Track Record of Sustainable Growth 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company
More informationFrom Turnaround to Sustainable Growth
From Turnaround to Sustainable Growth 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans,
More informationFrom Turnaround to Sustainable Growth. J.P. Morgan High Yield & Leveraged Finance Conference February 27 th, 2017
From Turnaround to Sustainable Growth J.P. Morgan High Yield & Leveraged Finance Conference February 27 th, 2017 1 Safe Harbor Statement This presentation contains forward-looking information that involves
More informationFrom Turnaround to Sustainable Growth
From Turnaround to Sustainable Growth 35 th Annual J.P. Morgan Healthcare Conference Steve MacMillan, Chairman, President and CEO 1 Safe Harbor Statement This presentation contains forward-looking information
More informationInvestor Relations Hologic
Investor Relations Hologic Hologic Announces Financial Results for Second Quarter of Fiscal 2017 -- GAAP Diluted EPS of $1.84 Increases 666.7%, Non-GAAP Diluted EPS of $0.50 Increases 6.4% -- -- Revenue
More informationBuilding a Sustainable Growth Company
Building a Sustainable Growth Company August 2015 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company
More informationFrom Turnaround to Sustainable Growth
From Turnaround to Sustainable Growth Raymond James 38 th Annual Institutional Investor Conference 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and
More informationThe Next Chapter: Leveraging Our Strengths to Accelerate Growth
The Next Chapter: Leveraging Our Strengths to Accelerate Growth Steve MacMillan Chairman, President and CEO 37 th Annual J.P. Morgan Healthcare Conference 1 Safe Harbor Statement This presentation contains
More informationBuilding a Track Record of Sustainable Growth
Building a Track Record of Sustainable Growth 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company
More informationLazard Capital Markets 9 th Annual Healthcare Conference
Lazard Capital Markets 9 th Annual Healthcare Conference November 14, 2012 Glenn P. Muir Executive VP and CFO 1 Forward-Looking Statements This presentation contains forward-looking information that involves
More informationBuilding a Track Record of Sustainable Growth
Building a Track Record of Sustainable Growth 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company
More informationBuilding a Sustainable Growth Company
Building a Sustainable Growth Company 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans,
More informationFrom Turnaround to Sustainable Growth
From Turnaround to Sustainable Growth 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans,
More informationFrom Turnaround to Sustainable Growth
From Turnaround to Sustainable Growth 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans,
More informationHologic Announces Third Quarter Fiscal 2012 Operating Results
1 of 9 26/11/2012 09:59 News Releases Hologic Announces Third Quarter Fiscal 2012 Operating Results BEDFORD, Mass., July 30, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX),
More informationNews Releases. Highlights of the quarter include:
1 of 11 26/11/2012 10:05 News Releases BEDFORD, Mass., Jan. 30, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics
More information1 sur 6 05/02/ :27
1 sur 6 05/02/2013 10:27 News Releases Hologic Announces First Quarter Fiscal 2013 Operating Results Record Revenues and Adjusted Net Income BEDFORD, Mass., Feb. 4, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic
More informationHOLOGIC ANNOUNCES THIRD QUARTER FISCAL 2009 OPERATING RESULTS. Solid Quarterly Revenues and Performance
For Immediate Release Contact: Deborah R. Gordon Vice President, Investor Relations Hologic, Inc. (781) 999-7716 HOLOGIC ANNOUNCES THIRD QUARTER FISCAL 2009 OPERATING RESULTS Solid Quarterly Revenues and
More informationNews Releases. Highlights:
1 of 15 26/11/2012 10:01 News Releases BEDFORD, Mass, April 30, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics
More informationHologic 3QFY17 Financial Results. Conference Call Prepared Remarks FINAL: 8/2/17. Note: May Change Slightly When Delivered
Hologic 3QFY17 Financial Results Conference Call Prepared Remarks FINAL: 8/2/17 Note: May Change Slightly When Delivered Mike Watts VP, Investor Relations & Corporate Communications Thank you,. Good afternoon
More informationHOLOGIC ANNOUNCES FOURTH QUARTER AND FISCAL 2011 OPERATING RESULTS. Record Revenues and Performance
For Immediate Release HOLOGIC ANNOUNCES FOURTH QUARTER AND FISCAL 2011 OPERATING RESULTS Record Revenues and Performance BEDFORD, Mass. (November 7, 2011) - Hologic, Inc. (Hologic or the Company) (Nasdaq:
More informationFiscal 2019 First Quarter Results. October 30, 2018
Fiscal 2019 First Quarter Results October 30, 2018 Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
More informationFourth Quarter Fiscal Year 2017
Fourth Quarter Fiscal Year 2017 October 25, 2017 J. Michael Bruff Vice President Investor Relations Mike.Bruff@Varian.com This presentation is intended exclusively for investors. It is not intended for
More informationMSCI THIRD QUARTER 2016
MSCI THIRD QUARTER 2016 Earnings Presentation October 27, 2016 2016 MSCI Inc. All rights reserved. Please refer to the disclaimer at the end of this document. FORWARD-LOOKING STATEMENTS Forward-Looking
More informationACI WORLDWIDE QUARTERLY AND FULL-YEAR EARNINGS PRESENTATION
ACI WORLDWIDE QUARTERLY AND FULL-YEAR EARNINGS PRESENTATION Private Securities Litigation Reform Act of 1995 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements
More informationXYLEM INC. Q EARNINGS RELEASE FEBRUARY 1, 2018
XYLEM INC. Q4 2017 EARNINGS RELEASE FEBRUARY 1, 2018 Q4 2017 EARNINGS RELEASE FORWARD-LOOKING STATEMENTS This presentation contains information that may constitute forward-looking statements. Forward-looking
More informationFourth Quarter and Full Year 2018 Financial Review and Analysis
Fourth Quarter and Full Year 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same periods in the prior
More informationXylem Agrees to Acquire Sensus to Broaden Portfolio and Enhance Growth Platform AUGUST 15, 2016
1 Xylem Agrees to Acquire Sensus to Broaden Portfolio and Enhance Growth Platform AUGUST 15, 2016 Forward-Looking Statements This presentation contains information that may constitute forward-looking statements.
More informationBaird Global Healthcare Conference
Baird Global Healthcare Conference Jason Meggs Chief Financial Officer September 6, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements
More informationFebruary 21, Conduent Q4 & FY 2017 Earnings Results
February 21, 2018 Conduent Q4 & FY 2017 Earnings Results Cautionary Statements Forward-Looking Statements This report contains forward-looking statements that involve risks and uncertainties. These statements
More informationAngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results Company posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance Q4 net sales of
More informationFourth Quarter 2017 Earnings
Fourth Quarter 2017 Earnings Jeff Jacobson, CEO Bill Osbourn, CFO January 31, 2018 http://www.xerox.com/investor Cautionary Statement Regarding Forward-Looking Statements This presentation, and other written
More informationFirst Quarter 2017 Earnings
First Quarter 2017 Earnings Jeff Jacobson, CEO Bill Osbourn, CFO April 25, 2017 http://www.xerox.com/investor Forward Looking Statements This presentation contains forward-looking statements as defined
More informationMcKesson Corporation Q2 Fiscal 2019 Financial Performance. Financial Results and Company Highlights October 25, 2018
McKesson Corporation Q2 Fiscal 2019 Financial Performance Financial Results and Company Highlights October 25, 2018 Forward-Looking Statements Some of the information in this presentation is not historical
More informationFiscal 2018 Third Quarter Results. 28 June 2018
Fiscal 2018 Third Quarter Results 28 June 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not
More informationIntuitive Surgical Announces Fourth Quarter Earnings
Intuitive Surgical Announces Fourth Quarter Earnings January 25, 2018 SUNNYVALE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ:ISRG), a global technology leader in robotic-assisted,
More informationIDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results
FOR IMMEDIATE RELEASE Contact: Kerry Bennett, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results Achieves revenue growth in Q4 of 14% on a reported
More informationSyneos Health. Q Financial Results. August 2, 2018
Syneos Health Q2 2018 Financial Results August 2, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements Except for historical information,
More informationQ4 AND FULL YEAR 2017 UPDATE FEBRUARY 16, 2018
Q4 AND FULL YEAR 2017 UPDATE FEBRUARY 16, 2018 SAFE HARBOR STATEMENT Forward-looking Statements This webcast presentation contains a number of forward-looking statements. Words such as gain, drive, invest,
More informationFourth Quarter and FY 2018 Earnings Presentation November 28, 2018
Fourth Quarter and FY 2018 Earnings Presentation November 28, 2018 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties,
More information2QFY17 Financial Results Conference Call Prepared Remarks FINAL: 5/10/17
2QFY17 Financial Results Conference Call Prepared Remarks FINAL: 5/10/17 Note: May Change Slightly When Delivered MIKE WATTS VP, Investor Relations and Corporate Communications Thank you,. Good afternoon
More informationQuad/Graphics Reports Second Quarter and Year-to-Date 2017 Results
FOR IMMEDIATE RELEASE Quad/Graphics Reports Second Quarter and Year-to-Date 2017 Results Consistent Execution of Strategic Objectives Drives Increased Net Earnings and Margins SUSSEX, WI, August 1, 2017
More informationicad REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS
icad REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Total revenues increased 17% year-over-year; up 29% excluding MRI asset sale Conference Call today at 4:30 p.m. ET NASHUA, N.H. (November 8, 2017) icad,
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Healthcare Conference, September 2017 NASDAQ: NOVT 1 Safe Harbor Statement The statements in this presentation
More informationHill-Rom Fourth Quarter 2016 Financial Results. November 3, 2016
Hill-Rom Fourth Quarter 2016 Financial Results November 3, 2016 Forward Looking Statements Certain statements in this presentation contain forward-looking statements, within the meaning of the Private
More informationForward-Looking Statements
Forward-Looking Statements Parts of this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve
More informationSalesforce Announces Fiscal 2015 Third Quarter Results
John Cummings Salesforce Investor Relations 415-778-4188 jcummings@salesforce.com Chi Hea Cho Salesforce Public Relations 415-281-5304 chcho@salesforce.com Salesforce Announces Fiscal 2015 Third Quarter
More informationUBS Healthcare Conference John J. Greisch, President and CEO. May 22, 2017
UBS Healthcare Conference John J. Greisch, President and CEO May 22, 2017 Forward Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities
More informationicad REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS
icad REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS Fourth quarter total revenues increased 14% year-over-year; total revenues increased 22% excluding MRI asset sale Conference call today
More informationSecond Quarter 2018 Financial Review and Analysis (preliminary, unaudited)
Second Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same period in the prior year. 1 Second
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Industrial Conference, November 2017 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement
More informationQ Supplement. August 6, 2014
Q2 2014 Supplement August 6, 2014 Disclaimer Please note that in this presentation, we may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking
More information2Q17 EARNINGS AUGUST 2017
2Q17 EARNINGS AUGUST 2017 FORWARD-LOOKING STATEMENTS The statements contained in this release that refer to plans and expectations for the next quarter, the full year or the future are forward-looking
More informationXerox Investor Handout as of Q Third Quarter 2018 Earnings
Xerox Investor Handout as of Q4 2018 Third Quarter 2018 Earnings http://www.xerox.com/investor Forward-Looking Statements This presentation, and other written or oral statements made from time to time
More informationMylan Q EARNINGS November 5, Q Earnings All Results are Unaudited
Mylan Q3 EARNINGS November 5, Q3 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to the safe harbor
More informationScience Applications International Corporation (SAIC) Third Quarter Fiscal Year 2018 Earnings Call. December 7, 2017
Science Applications International Corporation (SAIC) Third Quarter Fiscal Year 2018 Earnings Call December 7, 2017 Supplemental Financial Information Conference Call Information Date: December 7, 2017
More informationII-VI Incorporated Reports Fiscal 2017 Second Quarter Earnings; Achieves Record Bookings, Revenues and Backlog
375 Saxonburg Boulevard, Saxonburg, PA 16056 Tel. 724.352.4455 www.ii-vi.com Press Release II-VI Incorporated Reports Fiscal 2017 Second Quarter Earnings; Achieves Record Bookings, Revenues and Backlog
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013 Fourth Quarter Marks Third Consecutive Quarter of Improved Performance Natick, Mass. (February
More informationFirst Quarter 2019 Earnings Presentation February 6, 2019
First Quarter 2019 Earnings Presentation February 6, 2019 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many
More informationNews from Xerox. Xerox Reports Fourth-Quarter Earnings
News from Xerox For Immediate Release Xerox Corporation 45 Glover Avenue P.O. Box 4505 Norwalk, CT 06856-4505 tel +1-203-968-3000 Xerox Reports Fourth-Quarter Earnings GAAP EPS from continuing operations
More informationHorizon Global Third Quarter 2017 Earnings Presentation
Horizon Global Third Quarter 2017 Earnings Presentation October 31, 2017 Q1 2016 Earnings 1 Safe Harbor Statement Forward-Looking Statements This presentation may contain "forward-looking statements" as
More information2016 Financial Update and 2017 Outlook. Webcast Presentation December 13, 2016
2016 Financial Update and 2017 Outlook Webcast Presentation December 13, 2016 Safe Harbor Statement Note: All statements made herein that are not historical facts should be considered as forwardlooking
More information2018 THIRD QUARTER EARNINGS CALL
2018 THIRD QUARTER EARNINGS CALL Webcast: ir.avisbudgetgroup.com Dial-in: (630) 395.0021 Replay: (402) 220-0222 Passcode: 2995545 November 6, 2018 FORWARD-LOOKING STATEMENTS Statements about future results
More informationECOLAB SECOND QUARTER REPORTED DILUTED EPS $1.20 ADJUSTED DILUTED EPS $1.27, +13% FULL YEAR 2018 ADJUSTED DILUTED EPS FORECAST $5.
News Release Ecolab Inc. 1 Ecolab Place, St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 Andrew C. Hedberg (651) 250-2185 ECOLAB SECOND QUARTER REPORTED DILUTED EPS $1.20
More informationACI WORLDWIDE. July 27, 2017
ACI WORLDWIDE July 27, 2017 Private Securities Litigation Reform Act of 1995 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements based on current expectations
More informationMylan: Q EARNINGS August 8, Q Earnings All Results are Unaudited
Mylan: Q2 2018 EARNINGS August 8, 2018 Q2 2018 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationACI Worldwide, Inc. Reports Financial Results for the Quarter and Full Year Ended December 31, 2017
News Release ACI Worldwide, Inc. Reports Financial Results for the Quarter and Full Year Ended December 31, 2017 HIGHLIGHTS Revenue up 3% for the full year 2017* Cash flow from operations up 46% in 2017
More informationSecond Quarter 2018 Earnings Presentation May 8, 2018
Second Quarter 2018 Earnings Presentation May 8, 2018 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of
More informationInvestor Overview Presentation. August 2018
Investor Overview Presentation August 2018 Forward-Looking Statements Statements about future results made in this presentation constitute forward-looking statements within the meaning of the Private Securities
More informationPlease note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the presentation January 13, 2015 and should not be considered
More informationThird Quarter 2018 Financial Results. July 27, 2018
Third Quarter 2018 Financial Results July 27, 2018 This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included
More informationACI WORLDWIDE. November 2, 2017
ACI WORLDWIDE November 2, 2017 Private Securities Litigation Reform Act of 1995 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements based on current expectations
More informationSalesforce delivered the following results for its fiscal fourth quarter and full fiscal year 2018:
Exhibit 99.1 John Cummings Salesforce Investor Relations 415-778-4188 jcummings@salesforce.com Gina Sheibley Salesforce Public Relations 917-297-8988 gsheibley@salesforce.com Salesforce Announces Record
More informationSecond Quarter 2018 Earnings Call
Second Quarter 2018 Earnings Call July 26, 2018 Nick Zarcone President & Chief Executive Officer Varun Laroyia Executive Vice President & Chief Financial Officer Joe Boutross Vice President, Investor Relations
More informationHorizon Global First Quarter 2016 Earnings Presentation
Horizon Global First Quarter 2016 Earnings Presentation May 3, 2016 1 Safe Harbor Statement Forward-Looking Statements This presentation may contain "forward-looking statements" as defined in the Private
More informationWaters Corporation Management Presentation
Waters Corporation Management Presentation Chris O Connell Chairman & Chief Executive Officer January 2019 Cautionary Statements This presentation may contain forward-looking statements regarding future
More informationSECOND QUARTER 2018 EARNINGS CONFERENCE CALL
SECOND QUARTER 2018 EARNINGS CONFERENCE CALL Forward Looking Statements & Non-GAAP Disclaimer The following information may contain forward-looking statements, including forward-looking statements within
More informationQ EARNINGS CONFERENCE CALL BILL NUTI, CHAIRMAN & CEO MARK BENJAMIN, PRESIDENT & COO BOB FISHMAN, CFO
1 Q2 2017 EARNINGS CONFERENCE CALL BILL NUTI, CHAIRMAN & CEO MARK BENJAMIN, PRESIDENT & COO BOB FISHMAN, CFO July 20, 2017 NOTES TO INVESTORS FORWARD-LOOKING STATEMENTS. Comments made during this conference
More informationFiscal 2018 Fourth Quarter Results. July 26, 2018
Fiscal 2018 Fourth Quarter Results July 26, 2018 Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
More informationEarnings Presentation. October 27, 2011
Q1 Fiscal Year 2012 Earnings Presentation & Financial Results Supplement October 27, 2011 Safe Harbor Statement This presentation contains statements about our future expectations, plans and prospects
More informationACI Worldwide (ACIW) BAML 2014 Leveraged Finance Conference
ACI Worldwide (ACIW) BAML 2014 Leveraged Finance Conference December 2014 Private Securities Litigation Reform Act of 1995 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 523,335 $ 642,477 $ 2,178,178 $ 2,434,124 Cost of revenues 359,835 449,944 1,463,031 1,687,666 Gross
More information4Q18 EARNINGS. February NASDAQ: GRPN /
4Q18 EARNINGS February 2019 NASDAQ: GRPN / ir@groupon.com Forward-Looking Statements The statements contained in this release that refer to plans and expectations for the next quarter, the full year or
More informationicad REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS
icad REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS PowerLook Tomo Detection Version 2.0 Submitted for FDA Approval Conference call today at 4:30 p.m. ET NASHUA, N.H. (August 14, 2018) icad, Inc. (NASDAQ:
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers February 2018 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement The statements in this
More informationQ Earnings. October 31, 2018
Q4 2018 Earnings October 31, 2018 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning
More informationQ Conference Call. November 2, 2018
Q3 2018 Conference Call November 2, 2018 Forward Looking Statements This presentation contains forward-looking information regarding future events or the Company s future financial performance based on
More information2018 FOURTH QUARTER EARNINGS CALL
NORTH AMERICA S LEADING BUILDING MATERIALS DISTRIBUTOR RESIDENTIAL COMMERCIAL INTERIOR SOLAR 2018 FOURTH QUARTER EARNINGS CALL Forward Looking Statements / Non-GAAP Measures This presentation contains
More informationWyndham Destinations Reports Third Quarter 2018 Results
Wyndham Destinations Reports Third Quarter 2018 Results ORLANDO, Fla. (November 1, 2018) Wyndham Destinations, Inc. (NYSE:WYND), the world s largest vacation ownership and exchange company, today reported
More informationWaters Corporation Management Presentation. July 2018
Waters Corporation Management Presentation July 2018 Cautionary Statements This presentation may contain forward-looking statements regarding future results and events. For this purpose, any statements
More informationAVERY DENNISON ANNOUNCES SECOND QUARTER 2018 RESULTS
For Immediate Release AVERY DENNISON ANNOUNCES SECOND QUARTER 2018 RESULTS 2Q18 Reported EPS of $1.07 Adjusted EPS (non-gaap) of $1.66 2Q18 Net sales increased 14.0% to $1.85 billion Sales change ex. currency
More informationBIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS
BIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS WARSAW, Ind., January 8, 2013 Biomet, Inc. announced today financial results for its second fiscal quarter ended November 30, 2012.
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014 Marlborough, Mass. (October 22, 2014) -- Boston Scientific Corporation (NYSE: BSX) generated sales of
More informationEFI Q Earnings Call. July 20, 2015
EFI Q2 2015 Earnings Call July 20, 2015 Safe Harbor For Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities
More informationFirst Quarter 2017 Earnings Call
First Quarter 2017 Earnings Call May 4, 2017 Webcast: ir.avisbudgetgroup.com Dial-in: (630) 395-0021 Replay: (402) 998-0968 Passcode: 2995545 FORWARD- LOOKING STATEMENTS Statements about future results
More informationSalesforce Announces Record Third Quarter Revenue, Raises Full Year Fiscal 2018 Revenue Guidance
John Cummings Salesforce Investor Relations 415-778-4188 jcummings@salesforce.com Gina Sheibley Salesforce Public Relations 917-297-8988 gsheibley@salesforce.com Salesforce Announces Record Third Quarter
More informationjuly 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity
july 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity Safe Harbor Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More information